---
document_datetime: 2023-09-21 20:09:11
document_pages: 23
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/visudyne-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: visudyne-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.3737776
conversion_datetime: 2025-12-29 23:55:04.957143
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Visudyne

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0103            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 02/09/2020                          |                                             | Annex II and PL                  |           |
| IAIN/0102            | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                  | 20/11/2019                          |                                             | Annex II and PL                  |           |

Send us a question

Go to www.ema.europa.eu/contact

Telephone

+31 (0)88 781 6000

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/3110/ 201812   | Periodic Safety Update EU Single assessment - verteporfin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 05/09/2019   | n/a        |                        | PRAC Recommendation - maintenance   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| T/0100               | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 07/06/2019   | 25/07/2019 | SmPC, Labelling and PL |                                     |
| II/0098/G            | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification | 29/05/2019   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete   |            |            |             |                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0097 | Update of section 4.4. of the SmPC to amend the existing warning on hypersensitivity reactions and of section 4.8 to include 'Anaphylactic Reaction' with frequency 'not known'. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/07/2018 | 25/07/2019 | SmPC and PL | Cases of anaphylactic reactions have been observed in patients receiving Visudyne. If an anaphylactic or other serious allergic reaction occurs during or following infusion, administration of Visudyne should be discontinued immediately and appropriate therapy initiated. |

<div style=\"page-break-after: always\"></div>

| T/0096             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/04/2018   | 06/07/2018   | SmPC, Labelling and PL   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| II/0095            | Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning with information on localised skin necrosis upon extravasation and to add injection site necrosis as a new adverse drug reaction with frequency unknown. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 12/10/2017   | 06/07/2018   | SmPC, Labelling and PL   |                                   |
| IA/0094            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/03/2017   | n/a          |                          |                                   |
| PSUSA/3110/ 201512 | Periodic Safety Update EU Single assessment - verteporfin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 07/07/2016   | n/a          |                          | PRAC Recommendation - maintenance |
| IA/0093/G          | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for                                                                                                                                                                                                                                                                                                                                                                                                           | 13/04/2016   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

|                    | the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                      |            |            |                                  |                                                                                                                                                               |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0091            | Update of section 4.8 of the SmPC regarding hypersensitivity and vasovagal adverse reactions and the frequencies for retinal oedema and infusion- related chest pain. The Package Leaflet is updated accordingly. The MAH took the opportunity of this procedure to update the Product Information in line with the latest QRD template version 9.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 17/12/2015 | 19/12/2016 | SmPC, Annex II, Labelling and PL |                                                                                                                                                               |
| PSUSA/3110/ 201412 | Periodic Safety Update EU Single assessment - verteporfin                                                                                                                                                                                                                                                                                                                                                                                                         | 23/07/2015 | 18/09/2015 |                                  | Please refer to Visudyne-PSUSA/00003110/201412 ePAR: Scientific conclusions and ground recommending the variation to the terms of the marketing authorisation |
| IA/0089            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                     | 26/01/2015 | n/a        |                                  |                                                                                                                                                               |
| IAIN/0088          | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                        | 10/11/2014 | 18/09/2015 | SmPC, Labelling and PL           |                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IA/0087   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/10/2014   | n/a        |    |                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-----------------------------------|
| IA/0086/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 21/08/2014   | n/a        |    |                                   |
| PSUV/0085 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/07/2014   | n/a        |    | PRAC Recommendation - maintenance |
| N/0083    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/12/2013   | 18/09/2015 | PL |                                   |
| IA/0084/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/11/2013   | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|         | (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0248 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/12/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0079 | Update of sections 4.5, 4.8, 5.2 and 5.3 of the SmPC in order to: - include new text indicating theoretical potential interactions with drugs increasing verteporfin tissue- uptake, free radical scavengers and drugs antagonizing blood vessel occlusion (section 4.5) - include the events of macular edema and retinal edema as adverse drug reactions (section 4.8) - re-word and/or add new wording for the new sub- headings 'Distribution', 'Linearity/non-linearity', 'Special populations', 'Hepatic impairment', 'Renal impairment', 'Ethnic groups/races' and 'Effects on gender' (section 5.2) - include new and/or re-worded text under the new sub-headings: 'Single and repeated dose toxicity', 'Reproductive toxicity', 'Carcinogenicity' and 'Mutagenicity' (section 5.3) The Package Leaflet is updated in accordance. | 20/09/2012 | 23/10/2012 | SmPC, Annex II, Labelling and PL | In order to reflect the up to date available pre-clinical and clinical findings resulting from review of additional literature and already existing data and to bring the PI in line with the latest QRD template (version 8.1), the MAH included new text indicating theoretical potential drug-drug interactions; re-worded and/or added new wording for all new sub-headings under section 5.2 of the SmPC; included new and/or re-worded text under all new sub-headings under section 5.3 of the SmPC. In addition, based on temporal association, increase in annual reporting rates and the possible biological role of Visudyne, the MAH included the events of macular edema and retinal edema as adverse drug reactions. |

<div style=\"page-break-after: always\"></div>

|           | the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 8.1. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                               |            |     |               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------|
| IA/0081/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 07/09/2012 | n/a | specification |
| IG/0209/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of pharmacovigilance system                                                            | 17/08/2012 | n/a | the           |

<div style=\"page-break-after: always\"></div>

| IG/0148/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                | 22/02/2012   | n/a   |                 |                          |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|--------------------------|
| IB/0077     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                            | 05/01/2012   | n/a   |                 |                          |
| IA/0074/G   | application for a group of variations. B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding for batch release) | 09/08/2011   | n/a   | Annex II and PL | This was an manufacturer |
| IG/0088/G   | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons                                                                                                                                          | 11/07/2011   | n/a   |                 |                          |

<div style=\"page-break-after: always\"></div>

|           | involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                              |            |            |          | or organisations      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------|
| IG/0065   | B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                                                                                                                                                                                                                                                                         | 17/05/2011 | n/a        |          |                       |
|           | This was an application for a group of variations. Replacement of a manufacturer of a starting material used in the manufacture of verteporfin. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.d - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New manufacturer of material for which an assessment is viral safety and/or TSE risk | 14/04/2011 | 02/05/2011 |          | II/0072/G required of |
| IB/0073   | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits                                                                                                                                                                                                                                                           | 06/04/2011 | n/a        |          |                       |
| IG/0032/G | This was an application for a group of variations. To update the Detailed Description of the Pharmacovigilance System (DDPS) to version 9.0, to                                                                                                                                                                                                                                                         | 21/12/2010 | n/a        | Annex II |                       |

<div style=\"page-break-after: always\"></div>

|           | include: - a change in the deputy of the Qualified Person for Pharmacovigilance (QPPV); - a change in the major contractual arrangements. - administrative changes not impacting the operation of the pharmacovigilance system. Annex II.B has also been updated with the latest wording as per October 2010 CHMP procedural announcement. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s)   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0071/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/11/2010 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                       |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0069 | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/02/2010 | 05/05/2010 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of Visudyne continues to be favourable. The CHMP therefore recommended that a renewal can be |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                 |            |            |          | granted with unlimited validity. With this procedure the MAH also updated the product information (PI). This update was made so that the PI would be in line with the current QRD requirements.                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0070 | Update of the Detailed Description of the Pharmacovigilance system (DDPS). Changes to QPPV Update of DDPS (Pharmacovigilance)                   | 18/02/2010 | 23/03/2010 | Annex II | With this variation the MAH submitted a new version of the DDPS (core version 8.0 and product specific version 2.0) in accordance with the current Pharmacovigilance guideline. After assessing the documentation the CHMP concluded that the submitted DDPS contained all required elements. |
| IB/0064 | Addition of manufacturer for the active substance. IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer | 10/12/2009 | n/a        |          |                                                                                                                                                                                                                                                                                               |
| IB/0068 | IB_33_Minor change in the manufacture of the finished product                                                                                   | 03/12/2009 | n/a        |          |                                                                                                                                                                                                                                                                                               |
| IB/0067 | IB_37_b_Change in the specification of the finished product - add. of new test parameter                                                        | 03/12/2009 | n/a        |          |                                                                                                                                                                                                                                                                                               |
| IA/0066 | IA_37_a_Change in the specification of the finished product - tightening of specification limits                                                | 13/11/2009 | n/a        |          |                                                                                                                                                                                                                                                                                               |
| IA/0065 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                  | 09/11/2009 | n/a        |          |                                                                                                                                                                                                                                                                                               |
| II/0062 | To add a Detailed Description of the Pharmacovigilance system (DDPS) to Module 1.8.1. of the Visudyne Marketing Authorisation, in               | 23/10/2008 | 04/12/2008 | Annex II | With this variation the MAH submitted a first version of the DDPS (version 1.0 dated 30 June, 2008). After assessing the documentation the CHMP concluded that the submitted                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | accordance with the current pharmacovigilance guideline. Update of DDPS (Pharmacovigilance)                                                                                                                                                    |            |            |             | DDPS contained all required elements. The CHMP therefore accepted an update of Annex II to include an additional paragraph with details of the DDPS under the section \"other conditions\".                                                                                                                                                                                                                                                                                               |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0063 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                             | 18/08/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0061 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                              | 08/05/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0059 | Inclusion of \"retinal pigment epithelial tear\" in section 4.8 (Undesirable Effects) of the SPC, further to assessment of data performed by the MAH. Update of Summary of Product Characteristics                                               | 19/03/2008 | 23/04/2008 | SmPC        | Forty-six cases of 'retinal pigment epithelial tear'(RPET) were retrieved in Novartis' global safety database. In some cases the event took place within the first month of therapy and patients had no previous history of RPET. After analysis of these cases, the relationship between Visudyne and RPE tear cannot be totally excluded. For this reason \"retinal pigment epithelial tear\" has been included as an adverse reaction to Visudyne treatment in section 4.8 of the SPC. |
| II/0058 | Inclusion of information on excretion of Veterporfin in human milk in section 4.6 (Pregnancy and lactation) of the SPC, further to a re-assessment data performed by the MAH. Update of Summary of Product Characteristics and Package Leaflet | 19/03/2008 | 23/04/2008 | SmPC and PL | Based on the assessment of data submitted by the Marketing Authorisation Holder, the information in section 4.6 of the SPC has been updated to include the following statement \"Verteporfin and its diacid metabolic are excreted in human milk in low amounts\", describing the fact that if Visudyne is taken while breast-feeding, traces of the product are passed on to the nursing mother's milk. Section 2 of the PL has been modified accordingly.                               |
| II/0060 | Inclusion of safety information on post-marketing reports of Myocardial Infarction in section 4.8 of the                                                                                                                                       | 21/02/2008 | 17/03/2008 | SmPC and PL | Based on the assessment of PSUR 9, and the reccomendation from CHMP, the MAH has updated the                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | Summary of Product Characteristics (SPC). The Package Leaflet (PL) is being modified accordingly. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                       |            |            |                        | safety information in section 4.8 of the SPC to include the following statement \"Myocardial infarction has been reported particularly in patients with a previous cardiovascular history, sometimes within 48 hours after the infusion\". Section 4 of the PL is being modified accordingly, to include the following paragraph \"Heart attack has been reported, particularly in patients with a history of heart disease, sometimes within 48 hours after treatment with Visudyne\". Additionally, 'Slovakia' is being added to the Local representative details for this member state in the PL.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0057 | Deletion of manufacturing site IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                      | 29/11/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0056 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                 | 17/08/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0055 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                       | 17/08/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0053 | Update of the Summary of Product Characteristics (SPC) according to the 24 months results of the VIO study conducted in the occult indication as post- approval commitment for Visudyne. As a result, the Therapeutic Indication section (4.1) of the SPC has been amended to delete the indication \"treatment of patients with subfoveal occult CNV due to AMD with evidence of recent or ongoing disease progression\". | 26/04/2007 | 05/06/2007 | SmPC, Labelling and PL | Please refer to the Scientific Discussion H-305-II-53-AR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | Leaflet) has been amended accordingly and the Product Information has also been updated according to the latest QRD template. Furthermore, the contact details of the local representatives for the two new EU Member States, Romania and Bulgaria have been included in the PL. Update of Summary of Product Characteristics and Package Leaflet   |            |            |      |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IA/0054 | IA_06_a_Change in ATC code: Medicinal products for human use                                                                                                                                                                                                                                                                                        | 24/04/2007 | n/a        | SmPC |
| II/0052 | Change(s) to the manufacturing process for the finished product Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                     | 24/01/2007 | 19/02/2007 |      |
| IB/0050 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                                                                                                                | 11/12/2006 | n/a        |      |
| IB/0051 | IB_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                                                                                                                    | 06/12/2006 | n/a        |      |
| II/0049 | Change(s) to the manufacturing process for the active substance Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                     | 18/10/2006 | 23/10/2006 |      |

<div style=\"page-break-after: always\"></div>

| II/0046   | Quality changes                                                                                  | 23/03/2006   | 28/03/2006   |    |
|-----------|--------------------------------------------------------------------------------------------------|--------------|--------------|----|
| N/0047    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/03/2006   | n/a          | PL |
| II/0044   | Quality changes                                                                                  | 23/02/2006   | 28/02/2006   |    |
| II/0043   | Quality changes                                                                                  | 23/02/2006   | 28/02/2006   |    |
| IB/0045   | IB_24_Change in synthesis or recovery of non- pharmacopoeial excipient (when descr. in dossier)  | 18/01/2006   | n/a          |    |
| II/0036   | Quality changes                                                                                  | 14/12/2005   | 22/12/2005   |    |
| IB/0042   | IB_37_b_Change in the specification of the finished product - add. of new test parameter         | 20/12/2005   | n/a          |    |
| IB/0041   | IB_26_b_Change in the specification of immediate packaging - addition of new test parameter      | 20/12/2005   | n/a          |    |
| IB/0035   | IB_33_Minor change in the manufacture of the finished product                                    | 09/11/2005   | n/a          |    |
| IA/0040   | IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits   | 09/11/2005   | n/a          |    |
| IA/0039   | IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits   | 09/11/2005   | n/a          |    |
| IA/0038   | IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits   | 09/11/2005   | n/a          |    |

<div style=\"page-break-after: always\"></div>

| IA/0037   | IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits                                                                                                                                                                                                                                                                                      | 09/11/2005   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0034    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                    | 30/09/2005   | n/a        | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0033   | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                                                                                                                                                | 18/08/2005   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0032   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                  | 21/07/2005   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| R/0031    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                             | 21/04/2005   | 04/07/2005 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0029   | This variation relates to an update of SPC section 5.1 (Pharmacodynamic properties) to include the results of the 60 months BPD OCR 002 (TAP) A&B clinical study extension in patients with age-related degeneration with subfoveal choroidal neovascularisation.The Package Leaflet has been amended accordingly. Update of Summary of Product Characteristics and Package Leaflet | 17/02/2005   | 29/03/2005 | SmPC and PL                      | The initial approval for patients with classic-containing, subfoveal choroidal neovascularization due to age-related macular degeneration was based on the 2-year results of the clinical studies BPD OCR 002 A and 002 B (TAP) in which a total of 609 adult patients participated ( 402 were randomised to verteporfin and 207 to placebo). Study BPD952A2301 was a 3 year open label extension of TAP A and TAP B studies. The TAP Extension study included 476 patients in total. Of these patients 320 were long term verteporfin-treated patients; 134 were \"previously placebo\" patients treated with verteporfin; 22 \"previously placebo\" patients not treated with verteporfin.In patients followed from Month 24 onwards and treated with uncontrolled, open-label Visudyne treatment as needed, long-term extension data suggest that Month 24 vision outcomes may |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                     |            |            |             | be sustained for up to 60 Months. In the TAP study in all lesion types, the average number of treatments per year was 3.5 in the first year after diagnosis and 2.4 in the second for the randomised placebo-controlled phase and 1.34 in the third phase, 0.4 in the fourth and 0.1 in the fifth year for the open label extension phase. No additional safety concern was identified.The Package Leaflet has been amended accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027 | The Marketing Authorisation Holder applied to amend SPC sections 4.4 (Special warnings and special precautions for use) and 4.8 (Undesirable effects) following the assessment of the fifth PSUR.The Package Leaflet has been amended accordingly. Update of Summary of Product Characteristics and Package Leaflet | 17/02/2005 | 29/03/2005 | SmPC and PL | The CHMP concluded from the assessment of the fifth PSUR that the MAH should provide a safety overview on vision decrease. This overview was submitted in January 2004 and the CHMP requested that the wording concerning visual acuity decrease should be updated. In this variation the MAH applied for an update of the description of visual acuity decrease in section 4.8 of the SPC.Section 4.4 of the SPC provided guidance on precautions to avoid photosensitivity reactions and lists examples of bright light sources which could cause photosensitivity reactions. Two publications document photosensitivity reactions following use of pulse-oximeters, in patients who had undergone photodynamic therapy. For this reason \"prolonged exposure to light from light emitting medical devices such as pulse oximeters should also be avoided for 48 hours following Visudyne administration\" was added in section 4.4.Infusion related back/ chest pain was evaluated in PSUR 5 and previous PSURs and the MAH proposed a rewording of the description of the infusion related pain.Extravasation of verteporfin can lead to local photosensitivity reactions if the extravasation area is exposed to light. The MAH proposed to add to the warning regarding extravasation in section 4.4 of the SPC \"especially if exposed to light\". This |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                            |            |            |             | emphasizes the importance of protecting the area from light and is consistent with the already existing guidance to cover the extravasation area to avoid exposure to light.The Package Leaflet has been amended accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026 | This variation relates to an update of SPC section 5.1 (Pharmacodynamic properties) to include the results of the 60 months VIP clinical study extension in patients with pathological myopia.The Package Leaflet has been amended accordingly. Update of Summary of Product Characteristics and Labelling | 17/02/2005 | 29/03/2005 | SmPC and PL | The indication of photodynamic therapy (PDT) in myopic eyes with subfoveal choroidal neovascularisation was approved on the basis of the one-year results of the controlled study BPD OCR 003 PM (VIP) in which a total of 120 adult patients participated (81 were randomized to verteporfin and 39 to placebo). In order to confirm the one- year results, a second analysis was performed when all patients had completed 2 years of follow-up. On the basis of the 2-year results provided by the MAH in July 2001 the CHMP concluded that the difference between treatment groups, for visual acuity (mean, median or distribution of changes) examined in its entirety, remained favourable for verteporfin during the 2-year study duration, although, the responder rate was lower than the responder rate at 1 year. The MAH submitted in this variation the results of the 3 year follow up study (BPD952A2302), an open label extension study in patients with subfoveal choroidal neovascularisation due to pathological myopia. The VIP-PM Extension study included 96 (80%) of the 120 patients included in the BPD OCR 003 PM (VIP) study. Of the 81 verteporfin-treated patients, who participated in the BPD OCR 003 PM (VIP) study, 67 (83%) enrolled in the VIP-PM Extension study.In patients followed from Month 24 onwards and treated with uncontrolled, open-label Visudyne treatment as needed, long-term extension data suggest that Month 24 vision outcomes may be sustained for up to 60 months. The average number of treatments |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                 |            |            |                  | per year was in the randomised placebo-controlled phase 3.5 in the first year after diagnosis, 1.8 in the second and in the open label extension phase 0.4 in the third year, 0.2 in the fourth and 0.1 in the fifth. No additional safety concern was identified.The Package Leaflet has been amended accordingly.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028 | Quality changes                                                                                                                                                                                 | 15/12/2004 | 26/01/2005 | SmPC             |                                                                                                                                                                                                                                                                                                                       |
| IB/0030 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                         | 14/01/2005 | n/a        |                  |                                                                                                                                                                                                                                                                                                                       |
| II/0024 | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                  | 21/10/2004 | 25/10/2004 |                  |                                                                                                                                                                                                                                                                                                                       |
| N/0025  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                | 18/08/2004 | n/a        | Labelling and PL |                                                                                                                                                                                                                                                                                                                       |
| N/0023  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                | 12/08/2004 | n/a        | Labelling        |                                                                                                                                                                                                                                                                                                                       |
| IB/0022 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                         | 19/05/2004 | n/a        |                  |                                                                                                                                                                                                                                                                                                                       |
| IB/0020 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure IB_12_b_01_Change in spec. of active subst./agent in manuf. of active subst. - test parameter AS | 19/05/2004 | n/a        |                  |                                                                                                                                                                                                                                                                                                                       |
| IA/0021 | IA_09_Deletion of manufacturing site                                                                                                                                                            | 16/04/2004 | n/a        |                  |                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | IA_13_a_Change in test proc. for active substance - minor change                                 | 09/03/2004   | n/a        |                        | IA/0019   |
|---------|--------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------|
| IA/0018 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure   | 09/03/2004   | n/a        |                        |           |
| IA/0017 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure   | 09/03/2004   | n/a        |                        |           |
| N/0016  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 08/12/2003   | 14/04/2004 | PL                     |           |
| I/0015  | IB_33_Minor change in the manufacture of the finished product                                    | 17/11/2003   | n/a        |                        |           |
| T/0014  | Transfer of Marketing Authorisation                                                              | 04/08/2003   | 22/09/2003 | SmPC, Labelling and PL |           |
| I/0013  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process   | 04/12/2002   | 14/01/2003 | Annex II and PL        |           |
| II/0012 | Change(s) to the manufacturing process for the finished product                                  | 21/11/2002   | 27/11/2002 |                        |           |
| I/0010  | 15_Minor changes in manufacture of the medicinal product                                         | 05/09/2002   | 24/09/2002 |                        |           |
| II/0009 | Update of Summary of Product Characteristics                                                     | 30/05/2002   | 22/08/2002 | SmPC                   |           |
| II/0005 | Extension of Indication                                                                          | 30/05/2002   | 22/08/2002 | SmPC and PL            |           |

<div style=\"page-break-after: always\"></div>

| II/0008   | Update of Summary of Product Characteristics and Package Leaflet     | 21/02/2002   | 24/05/2002   | SmPC and PL   |               |
|-----------|----------------------------------------------------------------------|--------------|--------------|---------------|---------------|
| I/0006    | 20a_Extension of shelf-life or retest period of the active substance | 07/11/2001   | 15/02/2002   |               |               |
| II/0007   | Change(s) to the manufacturing process for the finished product      | 17/01/2002   | 11/02/2002   |               |               |
| I/0004    | 20_Extension of shelf-life as foreseen at time of                    | 27/06/2001   | n/a          |               | authorisation |
| II/0001   | Extension of Indication                                              | 14/12/2000   | 20/03/2001   | SmPC and PL   |               |
| I/0003    | 12_Minor change of manufacturing process of the active substance     | 16/02/2001   | 11/03/2001   |               |               |